|
| Osteologix IND For NB S101 For Osteoporosis Accepted By FDA |
9 May 08, 10:11 |
|
| Osteologix, Inc. (OLGX.OB), a specialty biopharmaceutical company, announced that the U. S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its lead development candidate NB S101 (strontium malonate), for the treatment and prevention of osteoporosis. |
| more |
|
